Ipsen has been granted a patent for certain 1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives as bile acid modulators with potential in treating cardiovascular, metabolic, gastrointestinal, and liver diseases. The method involves administering the compounds to the subject for therapeutic benefits. GlobalData’s report on Ipsen gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Ipsen SA - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ipsen, Cancer treatment biomarkers was a key innovation area identified from patents. Ipsen's grant share as of February 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11891368B2) discloses a method for treating various diseases and disorders in a subject by administering a therapeutically effective amount of a compound of formula (I). The diseases and disorders targeted by this method include cardiovascular diseases, disorders of fatty acid metabolism, glucose utilization disorders, gastrointestinal diseases, and liver diseases. Specific conditions within these categories include hypercholesterolemia, diabetes mellitus, insulin resistance, obesity, inflammatory bowel disease, liver fibrosis, and hepatocellular carcinoma, among others.

The patent further details the specific compounds that can be used in the treatment method, including various derivatives of benzothiazepin and benzothiadiazepin. These compounds are categorized based on their chemical structure and include different isomers and forms. The method outlined in the patent aims to provide a novel approach to treating a wide range of diseases and disorders by utilizing these specific compounds. The diverse selection of compounds and the broad spectrum of diseases targeted highlight the potential versatility and effectiveness of this treatment method in addressing various medical conditions.

To know more about GlobalData’s detailed insights on Ipsen, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies